Tyme Technologies, Inc.

NasdaqCM:TYME Lagerbericht

Marktkapitalisierung: US$53.5m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Tyme Technologies Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Richie Cunningham

Geschäftsführender

US$1.3m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts41.97%
Amtszeit als Geschäftsführer1.8yrs
Eigentum des Geschäftsführersn/a
Durchschnittliche Amtszeit des Managements2.7yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder6.1yrs

Jüngste Management Updates

Recent updates

Seeking Alpha • Sep 15

Syros, Tyme Technologies jump more than 20% after hours as shareholders approve merger

Shareholders of Syros Pharmaceuticals (NASDAQ:SYRS) and Tyme Technologies (NASDAQ:TYME) on Thursday voted in favor of the merger between the two biotech companies. SYRS and TYME stock gained more than 20% each in aftermarket trading - SYRS +22% and TYME +24%. Both SYRS and TYME held special stockholder meetings to vote on the merger, the companies said in a statement. SYRS shareholders also voted in favor of the company's concurrent private investment in public equity (PIPE) financing. The closing of the merger and the PIPE financing are anticipated to take place on or around Sept. 16. Post the closing of the merger, the combined company will trade on the Nasdaq under the ticker symbol "SYRS". SYRS also announced a 1-for-10 reverse stock split, with the stock to begin trading on a split-adjusted basis on the Nasdaq on Sept. 19.
Analyseartikel • Aug 05

We Think Tyme Technologies (NASDAQ:TYME) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Jul 05

TYME stock surges on merger agreement and Syros Pharmaceuticals

Development stage biotech firms Syros Pharmaceuticals (SYRS) and Tyme Technologies (NASDAQ:TYME) announced on Tuesday that the companies entered into a definitive merger agreement following which Syros (SYRS) will acquire Tyme (TYME). Tyme (TYME) has added ~23% in the pre-market so far while Syros (SYRS) is trading ~6% higher. Per the terms, Syros (SYRS) will issue ~74.3M shares of its common stock to TYME investors and TYME stockholders are entitled to nearly 0.4312 shares of Syros (SYRS) common stock for each TYME stock they hold. The deal is worth about $60M net of wind-down and transaction expenses. Following the merger, the combined entity will be led by Syros’ existing management team and trade on Nasdaq under the ticker symbol “SYRS.” Separately, Syros (SYRS) disclosed an oversubscribed $130M financing of private investment in public equity (PIPE) to purchase a total of up to 138.1M additional shares of common stock at $0.94 apiece. In addition, Syros (SYRS) also announced an amendment to its senior secured loan facility with Oxford Finance LLC. The terms include one year extension to the interest-only payment period and maturity dates subject to conditions revising them to March 1, 2024, and February 1, 2026, respectively. The transactions are expected to close in H2 2022.
Seeking Alpha • May 26

Tyme Technologies: Net-Net Biopharma Exploring Strategic Alternatives

Tyme Technologies is a clinical-stage biopharma company trading at a large discount to net cash + marketable securities. After the company discontinued the development of its primary compound, they have announced exploration of strategic alternatives. Board seems to be leaning towards a sale of the company.
Analyseartikel • Mar 19

We Think Tyme Technologies (NASDAQ:TYME) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Dec 07

Tyme Technologies Offers Incredible Risk-Reward

Tyme Technologies recently reported their Q2 earnings that revealed the company only burned roughly $5M in cash with about $97M left in the bank. The small-cap sell-off has pushed the share price to fresh 52-week lows. I believe TYME has an incredible risk-reward at these prices. I review some of the company’s updates and point out a few bullish highlights for investors. In addition, I discuss some of my lingering downside risks for TYME. I update investors on my strategy for managing my TYME position and how I intend to take advantage of the sell-off.
Analyseartikel • Nov 19

Here's Why We're Not Too Worried About Tyme Technologies' (NASDAQ:TYME) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Aug 27

Tyme Technologies: The Market Missed The Bullish Memo

Tyme Technologies recently made some big moves following a strategic review. I believe the market has missed the bullish memo about these changes. I review some of these significant changes and provide a bullish memo for investors. In addition, I discuss how these changes have addressed my downside concerns. The recent sell-off provided me with an opportunity to load up near the 52-week lows. I update investors on my strategy for managing my TYME position.
Analyseartikel • Jul 19

We're Not Very Worried About Tyme Technologies' (NASDAQ:TYME) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analyseartikel • Mar 26

Here's Why We're Watching Tyme Technologies' (NASDAQ:TYME) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analyseartikel • Feb 19

Have Tyme Technologies, Inc. (NASDAQ:TYME) Insiders Been Selling Their Stock?

Investors may wish to note that an insider of Tyme Technologies, Inc. , Michael Demurjian, recently netted US$55k from...
Analyseartikel • Feb 02

Do Institutions Own Tyme Technologies, Inc. (NASDAQ:TYME) Shares?

A look at the shareholders of Tyme Technologies, Inc. ( NASDAQ:TYME ) can tell us which group is most powerful...
Analyseartikel • Dec 16

Have Insiders Sold Tyme Technologies, Inc. (NASDAQ:TYME) Shares Recently?

We wouldn't blame Tyme Technologies, Inc. ( NASDAQ:TYME ) shareholders if they were a little worried about the fact...
Analyseartikel • Dec 09

Is Tyme Technologies (NASDAQ:TYME) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Richie Cunningham im Vergleich zu den Einnahmen von Tyme Technologies verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Jun 30 2022n/an/a

-US$24m

Mar 31 2022US$1mUS$564k

-US$24m

Dec 31 2021n/an/a

-US$24m

Sep 30 2021n/an/a

-US$25m

Jun 30 2021n/an/a

-US$26m

Mar 31 2021US$2mUS$194k

-US$29m

Vergütung im Vergleich zum Markt: RichieDie Gesamtvergütung ($USD1.34M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD622.00K).

Entschädigung vs. Einkommen: RichieDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Richie Cunningham (51 yo)

1.8yrs
Amtszeit
US$1,344,080
Vergütung

Mr. Richard Cunningham, also known as Richie, serves as Chief Executive Officer and Director at Tyme Technologies, Inc. since November 23, 2020. Mr. Cunningham had been the Chief Executive Officer and Pres...

Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Richard Cunningham
CEO & Director1.8yrsUS$1.34mkeine Daten
Steven Hoffman
Co-Founder & Director9.2yrsUS$2.60m11.63%
$ 6.2m
Frank Porfido
Chief Financial Officer1.3yrsUS$1.29m0.0058%
$ 3.1k
James Biehl
Chief Legal Officer & Secretary4yrsUS$1.19m0.061%
$ 32.7k
Jonathan Eckard
Chief Business Officer3.5yrsUS$858.79kkeine Daten
Jan Van Tornout
Acting Chief Medical Officer1.4yrskeine Daten0.0057%
$ 3.1k
2.7yrs
Durchschnittliche Betriebszugehörigkeit
58yo
Durchschnittliches Alter

Erfahrenes Management: TYMEDas Führungsteam des Unternehmens gilt als erfahren (2.7 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Richard Cunningham
CEO & Director1.8yrsUS$1.34mkeine Daten
Steven Hoffman
Co-Founder & Director7.5yrsUS$2.60m11.63%
$ 6.2m
Timothy Tyson
Independent Director7.5yrsUS$138.73k0.0034%
$ 1.8k
Donald DeGolyer
Independent Director4.3yrsUS$146.99kkeine Daten
Douglas Michels
Independent Chairman3.9yrsUS$166.34k0.064%
$ 34.2k
David Carberry
Independent Director5.5yrsUS$148.24k0.058%
$ 31.1k
Gerald Sokol
Independent Director & Member of Medical Advisory Board7.5yrsUS$122.87k0.0034%
$ 1.8k
Suresh Chari
Member of Medical Advisory Board6.7yrskeine Datenkeine Daten
Paul Oberstein
Member of Medical Advisory Boardno datakeine Datenkeine Daten
Marcus Noel
Member of Medical Advisory Boardno datakeine Datenkeine Daten
Allyson Ocean
Member of Medical Advisory Boardno datakeine Datenkeine Daten
Vincent Picozzi
Member of Medical Advisory Boardno datakeine Datenkeine Daten
6.1yrs
Durchschnittliche Betriebszugehörigkeit
65yo
Durchschnittliches Alter

Erfahrener Vorstand: TYMEDie Vorstandsmitglieder gelten als erfahren (6.1 Jahre durchschnittliche Amtszeit).

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2022/09/16 08:58
Aktienkurs zum Tagesende2022/09/16 00:00
Gewinne2022/06/30
Jährliche Einnahmen2022/03/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Tyme Technologies, Inc. wird von 3 Analysten beobachtet. dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
Arlinda LeeCanaccord Genuity
Joshua SchimmerEvercore ISI
Swayampakula RamakanthH.C. Wainwright & Co.